{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:34:40Z","timestamp":1784810080490,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.clml.2017.12.007","type":"journal-article","created":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T21:50:45Z","timestamp":1514584245000},"page":"145-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Consolidation Radiation Therapy for Patients With Advanced Hodgkin Lymphoma in Complete Metabolic Response According to PET-CT or Gallium Imaging"],"prefix":"10.1016","volume":"18","author":[{"given":"Erin J.","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Torok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo","family":"Chino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard R.","family":"Prosnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne W.","family":"Beaven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris R.","family":"Kelsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.12.007_bib1","unstructured":"NIH. National Cancer InstituteNational Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Hodgkin Lymphoma 2016, Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html, Accessed: January 16, 2018."},{"key":"10.1016\/j.clml.2017.12.007_bib2","unstructured":"Cancer Research UK. Hodgkin lymphoma incidence statistics 2016, Available at: http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/hodgkin-lymphoma\/incidence, Accessed: January 16, 2018."},{"key":"10.1016\/j.clml.2017.12.007_bib3","doi-asserted-by":"crossref","first-page":"725219","DOI":"10.1155\/2011\/725219","article-title":"Incidence patterns and outcomes for Hodgkin lymphoma patients in the United States","volume":"2011","author":"Shenoy","year":"2011","journal-title":"Adv Hematol"},{"key":"10.1016\/j.clml.2017.12.007_bib4","doi-asserted-by":"crossref","first-page":"djv018","DOI":"10.1093\/jnci\/djv018","article-title":"Late morbidity and mortality in patients with Hodgkin lymphoma treated during adulthood","volume":"107","author":"Matasar","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2017.12.007_bib5","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.12.007_bib6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin disease: report of an intergroup trial","volume":"21","author":"Duggan","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.12.007_bib7","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1200\/JCO.2010.30.9799","article-title":"Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP\/EBV\/CAD in patients with newly diagnosed advanced-stage Hodgkin lymphoma: a study from the Intergruppo Italiano Linfomi","volume":"29","author":"Chisesi","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.12.007_bib8","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2017.12.007_bib9","unstructured":"National Comprehensive Cancer Network, Hodgkin Lymphoma Version 1. 2018, Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf, Accessed: January 16, 2018."},{"key":"10.1016\/j.clml.2017.12.007_bib10","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(13)70341-3","article-title":"Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin lymphoma: a systematic review and network meta-analysis","volume":"14","author":"Skoetz","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.12.007_bib11","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa022628","article-title":"Involved-field radiotherapy for advanced Hodgkin lymphoma","volume":"348","author":"Aleman","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.12.007_bib12","doi-asserted-by":"crossref","first-page":"903","DOI":"10.7326\/0003-4819-120-11-199406010-00002","article-title":"Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study","volume":"120","author":"Fabian","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2017.12.007_bib13","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.12.007_bib14","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A\u00a0prognostic score for advanced Hodgkin disease. International Prognostic Factors Project on Advanced Hodgkin Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.12.007_bib15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.12.007_bib16","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0360-3016(03)00130-5","article-title":"Consolidation radiotherapy in the treatment of advanced Hodgkin disease: is it dead?","volume":"56","author":"Prosnitz","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2017.12.007_bib17","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1200\/JCO.1998.16.3.818","article-title":"Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin disease. International Database on Hodgkin Disease Overview Study Group","volume":"16","author":"Loeffler","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.12.007_bib18","first-page":"2246","article-title":"Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin disease: results of the groupe d\u2019etudes des lymphomes de l'Adulte H89 trial","volume":"95","author":"Ferme","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.12.007_bib19","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.12.007_bib20","doi-asserted-by":"crossref","first-page":"9208","DOI":"10.1200\/JCO.2005.03.2151","article-title":"Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)","volume":"23","author":"Johnson","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.12.007_bib21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1200\/JCO.1988.6.4.603","article-title":"Combined modality therapy for advanced Hodgkin disease: 15-year follow-up data","volume":"6","author":"Prosnitz","year":"1988","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.12.007_bib22","first-page":"871","article-title":"Combined modality therapy for advanced Hodgkin disease: long-term followup data","volume":"66","author":"Prosnitz","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clml.2017.12.007_bib23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1148\/107.1.187","article-title":"Low dose radiation therapy and combination chemotherapy in the treatment of advanced Hodgkin disease","volume":"107","author":"Prosnitz","year":"1973","journal-title":"Radiology"},{"key":"10.1016\/j.clml.2017.12.007_bib24","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim\u00a0PET-CT scan in advanced Hodgkin lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.12.007_bib25","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.12.007_bib26","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1080\/10428190701559140","article-title":"Randomized comparison of consolidation radiation versus observation in bulky Hodgkin lymphoma with post-chemotherapy negative positron emission tomography scans","volume":"48","author":"Picardi","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.12.007_bib27","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results\u00a0of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andre","year":"2017","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017314969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017314969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:38Z","timestamp":1761870638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017314969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S2152265017314969"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.12.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consolidation Radiation Therapy for Patients With Advanced Hodgkin Lymphoma in Complete Metabolic Response According to PET-CT or Gallium Imaging","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}